Searchable abstracts of presentations at key conferences in endocrinology

ea0086p322 | Endocrine Cancer and Late Effects | SFEBES2022

Investigating the role of cell fate regulator ASCL1 in driving and maintaining lethal neuroendocrine castrate resistant prostate cancer

Bruce Isla , Pang Lisa , Poole Amy , Fraser Jennifer

Neuroendocrine castrate resistant prostate cancer (NE-CRPC) is a lethal CRPC subtype that arises as prostate cancer cells transdifferentiate to neuroendocrine cells, evading the potent selective pressure of androgen deprivation therapies (ADT). Currently, clinicians lack biomarkers to detect NE-CRPC evolution and specific therapies to target it. With ~50% of prostate cancer (PC) patients receiving ADT and NE-CRPC accounting for ~25% of CRPC deaths, CRPC and NE-CRPC are a signi...